First-in-Human Study With GNbAC1 in Healthy Volunteers

NCT01699555 | Completed Phase 1

• 1 other identifier: GNC-001
• Study Type: interventional
• Target: 33
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to assess the safety and tolerability of single ascending doses of GNbAC1 in healthy male subjects.

Conditions

Multiple Sclerosis

Keywords

Multiple sclerosis; GNbAC1; Monoclonal antibody; Multiple Sclerosis Associated Retrovirus (MSRV); Temelimab

Outcome Measures

Primary Outcomes (1)

• number of reported adverse events for healthy male subjects receiving single ascending doses of GNbAC1.

  the number of adverse events along with the results of physical examinations, ECG and clinical laboratory tests will be used to determine the safety profile of GNbAC1.

  64 days

Secondary Outcomes (2)

• pharmacokinetics (PK) characteristics following administration of single ascending doses of GNbAC1 in healthy male subjects

  64 days

• immunogenicity of GNbAC1

  64 days

Study Arms (2)

GNbAC1

EXPERIMENTAL

Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg

Biological: GNbAC1

GNbAC1 placebo

PLACEBO COMPARATOR

Single dose intravenous (IV) GNbAC1 placebo

Biological: GNbAC1 placebo

Interventions

GNbAC1 BIOLOGICAL

Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg

GNbAC1

GNbAC1 placebo BIOLOGICAL

Single dose intravenous (IV) GNbAC1 placebo

GNbAC1 placebo

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male healthy subjects, 18-55 years of age and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram and laboratory tests at Screening and confirmed at baseline.
• Clinically acceptable for the purposes of the study sitting blood pressure and pulse rate, i.e.: BP: 100 - 150 mm Hg systolic, 50 - 95 mm Hg diastolic and pulse rate: 45 - 100 bpm. Blood pressure and pulse will be measured after 3 minutes resting in a sitting position.
• Body mass index between 18.5 and 30.0 kg/m2 and body weight in the 50 - 95 kg range.
• No need for regular concomitant medication
• Subjects with partners of childbearing potential have to use adequate contraception during, and for at least the four weeks after administration of study medication. Adequate contraception is defined as usage by at least one of the partners of a barrier method of contraception, together with usage by the female partner, commencing at least three months prior to Screening, of a stable regimen of any form of hormonal contraception or an intra-uterine device. Use of abstinence alone is not considered adequate. Use of a barrier method alone is considered adequate only if the subject was vasectomized at least six months prior to Screening.
• Ability to communicate well with the investigator and comply with the requirements of the entire study.
• The subject has given written consent to participate in the study.

You may not qualify if:

• History of serious adverse reactions or hypersensitivity to any drug.
• Presence or history of any allergy requiring acute or chronic treatment (seasonal allergic rhinitis which requires no treatment may be tolerated).
• Abnormal physical findings of clinical significance at the Screening or baseline examination which would interfere with the objectives of the study.
• Need of any prescription medication within 30 days prior to the administration of the drug and/or nonprescription medication within 7 days prior to the administration of the drug or anticipated need for any concomitant medication during the study.
• Participation in a clinical trial during the previous 4 weeks, i.e. from completion of the previous trial to the planned first administration of the current trial.
• Loss of 500 mL blood or more during the 3 month period before the screening visit of the study, e.g. as a donor.
• Existence of any surgical or medical condition which might relevantly interfere with the subject safety, the distribution, metabolism or excretion of the drug or the study assessments, i.e. impaired renal or hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms of pronounced constipation or diarrhea or conditions associated with total or partial obstruction of the urinary tract.
• Symptoms of a significant (upon Investigator's medical judgment) somatic or mental illness in the two week period preceding drug administration.
• History or clinical evidence of significant cardiovascular, respiratory, renal, hepatic,gastrointestinal, hematological, neurologic or other disease.
• History of hepatitis B and / or C and / or positive serology results which indicate the presence of hepatitis B and / or C.
• Positive results from the HIV serology.
• Positive for MSRV env by RNA PCR
• Clinically significant abnormal laboratory values (as determined by the Principal Investigator in consultation with the sponsor) at the Screening or baseline evaluation.
• History of serious mental disorders.
• History of alcohol or drug abuse in the last 3 years.

Sponsors & Collaborators

• GeNeuro Innovation SAS: lead

Related Publications (1)

• Curtin F, Lang AB, Perron H, Laumonier M, Vidal V, Porchet HC, Hartung HP. GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study. Clin Ther. 2012 Dec;34(12):2268-78. doi: 10.1016/j.clinthera.2012.11.006. Epub 2012 Nov 29.

  PMID: 23200102 RESULT

MeSH Terms

Conditions

Multiple Sclerosis

Interventions

temelimab

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• Thierry Kamtchoua, M.D

  Covance Clinical Research Unit AG

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 27, 2012
• First Posted: October 3, 2012
• Study Start: July 1, 2011
• Primary Completion: March 1, 2012
• Study Completion: August 1, 2012
• Last Updated: October 20, 2020

Record last verified: 2012-12